WuXi , GSK in License Agreement on Multiple Novel Bi- & Multi-specific T Cell Engagers

 

• WuXi Biologics will provide an exclusive license to GSK for one preclinical bi-specific T cell engaging (TCE) antibody and the option of three additional bi-/multi-specific TCE antibodies developed using WuXi Biologics' proprietary technology platforms
• WuXi Biologics will receive an upfront payment of $40 million and tiered royalties on net sales

https://www.biospace.com/article/releases/wuxi-biologics-and-gsk-enter-into-license-agreement-on-multiple-novel-bi-and-amp-multi-specific-t-cell-engagers/